



(11) **EP 1 943 251 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07D 473/00 (2006.01) **C07H 19/16** (2006.01)
A61K 31/52 (2006.01) **A61P 9/06** (2006.01)
A61P 3/10 (2006.01) **A61P 25/00** (2006.01)

(48) Corrigendum issued on:
23.03.2011 Bulletin 2011/12

(86) International application number:
PCT/US2006/039975

(45) Date of publication and mention
of the grant of the patent:
09.02.2011 Bulletin 2011/06

(87) International publication number:
WO 2007/047401 (26.04.2007 Gazette 2007/17)

(21) Application number: **06825861.5**

(22) Date of filing: **11.10.2006**

(54) **A1 ADENOSINE RECEPTOR AGONISTS**

A1-ADENOSINREZEPTORAGONISTEN

AGONISTES DU RÉCEPTEUR A1 DE L'ADÉNOSINE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR
Designated Extension States:
AL BA HR MK RS

- **LI, Xiaofen**
Mountain View, CA 94040 (US)
- **ZABLOCKI, Jeff**
Los Altos, CA 94022 (US)

(30) Priority: **13.10.2005 US 726616 P**

(43) Date of publication of application:
16.07.2008 Bulletin 2008/29

(74) Representative: **Schnappauf, Georg et al**
Dr. Volker Vossius
Patent- und Rechtsanwaltskanzlei
Geibelstrasse 6
81679 München (DE)

(73) Proprietor: **Gilead Palo Alto, Inc.**
Foster City, CA 94404 (US)

(56) References cited:
WO-A-00/23457 WO-A-02/094273
WO-A-03/014137 WO-A-2004/069185

(72) Inventors:
• **ELZEIN, Elfatih**
Fremont, CA 94555 (US)

EP 1 943 251 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).